Innovative transplantation technique helps find early signs of type 1 diabetes

By the time type 1 diabetes is diagnosed, most of the insulin-producing beta cells have already been destroyed. Now, using an innovative transplantation technique, researchers at Karolinska Institutet and University of Miami Miller School of Medicine have been able to intervene to save the beta cells in mice by discovering early signs of the disease. The study is published in Diabetologia, the scientific journal of the European Association for the Study of Diabetes (EASD).

Type 1 diabetes is caused when the insulin-producing beta cells in the endocrinal part of the pancreas - the islets of Langerhans - are destroyed by an autoimmune attack. There are currently no drugs to prevent the disease developing.

Understanding the mechanisms that give rise to type 1 diabetes is essential to the development of drugs able to prevent damage to the beta cells. One major hurdle is that the disease is often discovered too late, when the beta cells are already destroyed. Scientists therefore need to find a robust diagnostic method that involves identifying early autoimmune markers.

Transplanted to the eye

The present study shows that the islets of Langerhans transplanted to the anterior chamber of the eye can be important reporters of autoimmunity and the development of type 1 diabetes. By studying transplanted islets of Langerhans in a mouse model with type 1 diabetes, the researchers found that the islets showed signs of inflammation long before other indicators of the disease appeared.

"This information is important as it means that treatment can be given before the insulin-producing cells have been destroyed in the autoimmune attack, which is imperative if patients are to retain their ability to secrete insulin," says study leader Per-Olof Berggren, Professor at the Department of Molecular Medicine and Surgery and the Rolf Luft Research Center for Diabetes and Endocrinology at Karolinska Institutet in Sweden and Visiting Professor at the Diabetes Research Institute, University of Miami Miller School of Medicine (USA), who developed the transplantation technique.

Managed to retard the attack

On monitoring the graft in real time before and after the development of type 1 diabetes, Professor Berggren and his colleague Dr Midhat Abdulreda at the Diabetes Research Institute, University of Miami Miller School of Medicine, found that the transplanted islets were attacked by the immune system in a way similar to those in the liver during type 1 diabetes.

The infiltration of immune cells took place concurrently with the signs of autoimmunity, namely inflammation in the islets and later hyperglycemia. Guided by these early symptoms of an autoimmune reaction, the researchers were able to retard the attack on the islets with both systemic and local immunosuppression.

New transplantation strategy

Our study demonstrates the possibility of using eye-transplanted islets of Langerhans as a tool for improving the development of new drugs and, in combination with the local administration of immunosuppressive drugs, as a new clinical transplantation strategy for patients with type 1 diabetes,"

Per-Olof Berggren, study leader, Professor at the Department of Molecular Medicine and Surgery

Source:

Karolinska Institutet

Journal reference:

Berggren, P. et al. (2019) In vivo imaging of type 1 diabetes immunopathology using eye-transplanted islets in NOD mice. Diabetologia. doi.org/10.1007/s00125-019-4879-0

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Semaglutide may lower Alzheimer's risk in type 2 diabetes patients